SCM
TERN

Suvretta Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Suvretta Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,363,675
Closed -$8.95M – 109
2024
Q1 		$8.95M Sell
1,363,675
-4,473,451
-77% -$29.2M 0.33% 52
2023
Q4 		$37.9M Sell
5,837,126
-204,784
-3% -$1.08M 1.71% 20
2023
Q3 		$30.4M Buy
6,041,910
+480,075
+9% +$3.05M 1.64% 19
2023
Q2 		$48.7M Buy
5,561,835
+2,113,560
+61% +$24.6M 2.6% 10
2023
Q1 		$40.8M Hold
3,448,275
– – 1.72% 22
2022
Q4 		$35.1M Buy
+3,448,275
New +$23M 1.47% 29
2022
Q3 		– Sell
-1,238,800
Closed -$3.07M – 88
2022
Q2 		$3.07M Hold
1,238,800
– – 0.12% 71
2022
Q1 		$3.68M Hold
1,238,800
– – 0.11% 67
2021
Q4 		$8.76M Buy
1,238,800
+113,064
+10% +$942K 0.17% 64
2021
Q3 		$11.7M Buy
1,125,736
+600
+0.1% +$6.22K 0.2% 62
2021
Q2 		$13.8M Hold
1,125,136
– – 0.21% 72
2021
Q1 		$24.8M Buy
+1,125,136
New +$24.7M 0.37% 53

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Suvretta Capital Management's TERN Position: Q2 2024 in Review

Suvretta Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2024, closing a stake of 1,363,675 shares — an estimated $8.95M sold.

Suvretta Capital Management first reported a position in TERN in Q1 2021 and held it in 12 quarters. The position peaked at $48.7M in Q2 2023. 126 funds tracked by Wall St. Rank hold TERN as of Q2 2024.

  • Suvretta Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 1,363,675 Terns Pharmaceuticals shares in Q2 2024, an estimated $8.95M.
  • Suvretta Capital Management first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Suvretta Capital Management's Terns Pharmaceuticals position peaked at $48.7M in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2024.

Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.